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A greater number of adults with CV events were identified in the PFO
group (50) vs control group (34). p < 0.07. The proportion of adults with
The relative odds associated with a 80 mg/dl (1 STD) increase of fibrino-
gen (adjusted in multiple logistic regression for the above parameters) was
1.47 (90% CI1.22-1.77). Conclusion: Fibrinogen emerged as an independent
predictor of strokelTlA in CIHD pts.
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embolism, non-fatal myocardial infarction or vascular death. An interim anal-
ysis carried out on the first 582 patients irrespectively from treatment groups
showed an overall stroke rate (2.9%) and a frequency of primary end-points
(7.4%) very similar to those observed in the anticoagulant arm of a recently
published study (European Atrial Fibrillation Trial). The final results of the SIFA
trial should help to clarify the role of antiplatelet drugs in the prevention of
stroke in NVAF patients.
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1735-21 Fibrinogen is an Independent Predictor of Ischemic
StrokerrlA in Patients with Coronary Heart Disease
David Tanne, Uri Goldbourt, Michal Benderly, Valentina Boyko,
Henrietta Reicher-Reiss, Solomon Behar, Bezafibrate Infarction Prevention (SIP)
Study Group. Neufeld Cardiac Research Institute, Tel Hashomer, fsrael
In order to determine the association between baseline fibrinogen levels and
subsequent development of ischemic stroke or transient ischemic attack
(TIA) we followed prospectively patients (pts) with chronic ischemic heart
disease (CIHD) included in the BIP study for new cerebrovascular events.
This study includes 31 22 pts aged 45-74 with TC 180-250, triglycerides,
:,:300 and HDL :,:45 mg/dl without a prior stroke, randomized to either 400
mg/dl Bezalip Retard or placebo. The annual rate of cerebrovascular events
among these pts was 0.8% (69 pts - 12 TIA, 57 stroke). Fifty of the strokes
were cerebral infarction, 5 of uncertain type (probably ischemic) and 2 in-
tracerebral hemorrhage. Pts developing ischemic strokelTlA (67 pts) were
older than those without this complication (mean age 61.5 vs. 59.7 years).
had higher systolic blood pressure measurements (138 ± 21 vs. 133 ± 18
mmHg) and higher rate of severe (class 2-4) anginal syndrome (36% vs.
23%). History of diabetes (24% vs. 9%), peripheral vascular disease (10%
vs. 3%) and current smoking (19% vs. 11 %) were more prevalent among pts
with ischemic strokelTlA than among counterparts without this complication
(p < 0.05). Fibrinogen levels were significantly higher in pts subsequently de-
veloping ischemic strokelTlA (388 ± 70 vs. 349 ± 73 mg/dl, p < 0.0001). Age
adjusted ischemic strokelTlA rates/100 person years in fibrinogen quintiles
were as follows.
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1735-31 A Study of 1044 Consecutive Patients with Patent
Foramen Ovale: Association with Cryptogenic
Cerebrovascular Events in Adults
Sumita D. Paul, Mary Etta King, Michael H. Picard, Stella V. Brili, Peter Lang, John
B. Newell, Richard R. Liberthson, Ariane J. Marelli. Massachusetts General Hospital,
Harvard Medical School, Boston, MA
The natural history of patent foramen ovale (PFO) in association with cere-
brovascular (CV) events has not been described. With the development of
devices for non-surgical closure of atrial septal defect, it is possible that
the risk of PFO closure may be minimal. However, the potential benefit of
PFO closure remains unknown and difficult to assess due lack of adequate
data.
To determine the prevalence of PFO and its association with cryptogenic
(CRYP) and non-cryptogenic (NON) stroke, we examined the database of
37,940 consecutive pts who underwent echocardiography between 1984
to 1994, to identify pts diagnosed with PFO (n = 1044) and designed an
age-matched nested case-control study with 2088 pts to determine the as-
sociation of CV events to PFO. All CV events were confirmed by review of
medical records. NON stroke was defined: cardiogenic, atherosclerotic, la-
cunar, arteritis, aneurysm, hematoma. CRYP stroke was diagnosed by ex-
clusion when the event could not be ascribed to causes in the NON group.
Results: The age distribution is given below:
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Three-dimensional (3-D) vessel reconstruction using intravascular ultrasound
(IVUS) is limited by the lack of information on the real vessel curvatures and
the orientation of the IVUS catheter.
To overcome these limitations a method was developed using data ob-
tained from ANGiography and intravascular UltraSound (ANGUS). This tech-
nique provides real spatial geometry and orientation of coronary lumen and
plaque. The artery is studied by IVUS during a pull-back (PB) of the IVUS
catheter at a speed of 1 mm/s. Start and end of the PB are recorded by bi-
plane fluoroscopy (BF) and finally biplane coronary angiography (BA) is per-
formed without changes in geometrical X-ray settings.
Using a new computer program the contours of the lumen-plaque and
plaque-adventit;a boundaries are semi-automatically detected at 0.5 mm
intervals. BF allows geometrical reconstruction of the catheter trajectory,
which is the path of the IVUS transducer during PB. Combined use of the
IVUS data, the catheter trajectory and the lumen contours in the BA pro-
vides a unique 3-D reconstruction of coronary arteries without any evidence
of an additional unknown geometric factor. Studying the trajectory in a ves-
sel phantom of known dimensions a high accuracy was found (distance be-
tween reconstructed and real trajectory at any point <2 mm). First appli-
cation in a human right coronary artery in-vivo (length: 75 mm) showed a
difference of 2% between the length of the reconstructed trajectory and the
PB distance. Checking the locations of the origin of side-branches in the 3-D
reconstruction and BA differences of less than 2 mm were found. Location
and shape of stenoses in simulated projections of the reconstructed lumen
matched well with BA. However, at the site of a previous PTCA luminal hazi-
ness in angiography and dissection observed by IVUS may slightly reduce
the accuracy of this technique.
Thus combining ANGiography and intravascular UltraSound (ANGUS) is
promising and provides a unique reconstruction of 3-D coronary geometry.
Camelis J. Slager, Martin Laban, Clemens von Birgelen, Rob Krams, Jan
A.F. Oomen, Ad den Boer, Li Wenguang, Pim J. de Feyter, Patrick W Serruys. Jos
R.T.C. Roeland!. Thoraxcenter, Erasmus University Rotterdam, The Netherlands
ANGUS: A New Approach to Three-dimensional
Reconstruction of Geometry and Orientation of
Coronary Lumen and Plaque by Combined Use of
Coronary Angiography and IVUS
3, 28%). In all cases except in 1, in which balloon PTCA was used after RF,
RF was used alone. Pressure was maintained at the lowest level to assure
full balloon expansion, temperature was set to 55'C. After RF lumen area
increased from 2.3 ± 1.1 mm2 to 7.19 ± 1.8 mm2 (p < 0.001). After RF in 7
lesions (63%) plaque rupture was observed (1 partial; 2 extending to media;
4 with accompanying dissection). The main mechanism for the increase in
lumen area was: a) Plaque rupture and/or dissection n = 6 (54%); b) Plaque
compression n = 4 (36%); c) "Total artery" dilation n = 1 (9%).
In conclusion, the mechanism of luminal enlargement after RF, as viewed
with ICUS, was similar to that reported with conventional PTCA, with plaque
rupture/dissection followed by plaque compression being the main mecha-
nisms.
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Gabriella Cataldo, SIFA Study Group. Institute of Neurology, University of Rome "La
Sapienza~ Italy
The effect of oral anticoagulation for primary and secondary prevention of
stroke in patients with non-valvular atrial fibrillation (NVAF) has been clearly
shown in several studies. Still uncertain is the role of antiplatelet agents. The
SIFA is a multicenter open randomized trial which aims to compare the effi-
cacy and safety of an oral anticoagulant treatment (Wartarin to obtain an INR
of 2.0-3.5) with an antiplatelet drug (Indobufen, a reversible cyclooxygenase
inhibitor, 100-200 mg bid) in patients with NVAF and a recent (:,:14 days)
transient ischaemic attack or stroke. The study started in January 1991 and
is expected to be completed by December 1994. Nine hundred and fifty pa-
tients entered the trial and were treated for 12 months. The primary outcome
events were: non-fatal stroke (including cerebral haemorrhage), systemic
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Fibrillation: Results of the SIFA (Studio Italiano
Fibrillazlone Atriale) Trial
JACC February 1995
cryptogenic stroke was significantly higher in the PFO group (18/50,36%) vs
control group (5/34, 15%), p < 0.04.
Conclusions: 1. The prevalence of PFO decreases from the neonate to the
adult.
2. There is a high prevalence of cryptogenic stroke among adults with PFO
who have suffered a cerebrovascular event.
3. These results provide a baseline for designing future prospective stud-
ies of PFO and CV events, and randomized trials to determine the impact of
PFO closure.
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1735-41 Characteristics of Patent Foramen Ovale in Stroke
Patients: Two-dimensional and Biplane Contrast
Transesophageal Study
Stefano De Castro, Domenico Cartoni, Maurizia Rasura 1, Sergio Beni,
Alexia Anzini 1, Monica Moschini Antinori. Francesco Pelliccia, Paride Giannantoni.
Dept. of Clinical Medicine, "IE Sapienza" University, Rome, Italy; 1 Dept. of
Neuroscience, "La Sapienza'" University. Rome, Italy
Transesophageal echocardiography (TEE) has detected an increased preva-
lence of Patent Foramen Ovale (PFO) in patients with unexplained stroke. In
order to evaluate the morphological characteristics of PFO, 130 consecutive
stroke patients were studied. Of these, 21 with PFO (16%) were identified by
saline contrast TEE (Gr.A). They were matched for age and sex with 25 con-
trols (Gr.B) who had also recently had ischemic stroke but no cardiac sources
of emboli detected by TEE.
On TEE we measured: diameter of fossa ova lis (DFO); separation between
septum primum and secundum (MaxSep); thickness, length and mobility of
the fossa ovale membrane. With saline contrast injection, the number of mi-
crobubbles appearing in left atrium were counted: mild «10 mb), moderate
(10-20 mb) and severe (>20 mb).
Compared with Group B, Group A showed increased MaxSep (p < 0.0001)
and membrane mobility (p < 0.001). In addition, the degree of right to left
shunt was directly correlated to the increased in MaxSep (mild vs severe; p
< 0.0001).
In conclusion, the morphological aspect of FO in patients with ischemic
stroke and PFO, is cha racterized by an increased separation between septum
primum and septum secundum and greater mobility of the FO membrane.
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Role of Patent Foramen Ovale and Deep Venous
Thrombosis in 220 Patients with Unexplained Stroke
or Transient Ischemic Attack: A Prospective
Transthoracic and Transesophageal
Echocardiographic Study
Harald Lethen, Franz Beck, Gerlinde Kahn, Rolf Schneider 1, Ulrich Sliwka 1,
Andreas Franke, Frank A. Flachskampf, Johannes Noth 1, Peter Hanrath. Med
KJimk I, RWTH Aachen, Germany; 1 Depf. Neurology!», RWTH Aachen, Germany
To evaluate the additional value of biplane transesophageal (TEE) compared
to transthoracic (TIE) echo and the role of patent foramen ovale IPFO) and
deep vein thrombosis (DVT) in the work-up of embolic events, patients (pts)
with presumed cardiac embolic stroke or transient ischemic attack (TIA) (neu-
rovascular etiology was excluded by dopplersonography) were prospectively
studied by transthoracic and transesophageal contrast echo and phlebogra-
phy if PFO was present.
Results: 220 pts, 136 men (60 ± 15 years) were studied. In 140 of 220 pts
neuroimaging showed evidence of manifest stroke. TEE identified a poten-
tial cardiac source of embolism (left atrial thrombus [lAT], PFO, atrial septal
aneurysm [ASA], spontaneous contrast [sq, endocarditic valve lesions, mi-
tral valvular disease [MVDj and prosthetic head valves) in 43% of pts com-
pared with only 18% by TIE (p < 0.01). TEE was especially superior com-
pared to TIE for identifying LAT (10 versus 0 pts), SC (26 vs 6 pts), PFO
associated with ASA (16 vs 6 pts) and PFO alone (34 vs 20 pts). Phlebogra-
phy was performed in 50 pts with PFO. Of those pts 32 showed brain infarct
2: 1 cm diameter on neuroimaging, 18 pts had TIA. Phlebography revealed
clinically silent DVT only in pts with brain infarct (4 cases, 12.5%), no pt with
TIA had positive phlebography.
Conclusion: In this prospective study TEE detected significantly more po-
tential sources of embolism than TIE; moreover, phlebography in the pres-
ence of PFO and a clear-cut ischemic brain lesion on neuroimaging revealed
a 12.5% incidence of clinically unsuspected deep venous thrombosis. These
findings strongly suggest paradoxical embolism as an important mechanism
of stroke and support phlebography to define the relevance of PFO in the
stepwise work-up of pts with suspected cardiogenic stroke.
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Transesophageal Echocardiographic Evaluation of
Patients with Cryptogenic Stroke: Is Transthoracic
Echocardlography Helpful?
Barbara A. Pisani, Kwame O. Akosah, Christine Maxine, Walter Paulsen, Pramod
K. Mohanty. McGuire VA Medical Center and Medical College of Virginia, Richmond,
VA
Approximately 30--40% of ischemic strokes are believed to be cardiogenic
in origin. Despite its poor sensitivity transthoracic echocardiography (TIE) is
widely used to rule out cardiac source of emboli. Recently transesophagel
echocardiography (TEE) has shown higher sensitivity for detecting potential
sources of embolic stroke. However, the extent to which TEE findings alter
the initial treatment plan is unclear. We evaluated 112 patients who were
referred for TIE to rule out cardiac sources of stroke by both TIE and TEE.
Nineteen (17%) had a positive TIE compared to 64 (57%) with positive TEE.
In addition, 11 of the 64 (17%) with abnormal TEE had findings which clearly
redirected the treatment plan (myxoma = 4; thoracic aortic mass = 1; native
valve vegetation = 1; prosthetic valve vegetation = 1; valvular masses = 3).
One patient whose TIE was interpreted as left atrial ILA) myxoma had atrial
septal aneurysm (ASA) byTEE. This ASA protruded into the lA and simulated
as a "mass" on the TTE. A higher rate of detection of potential source for
emboli was noted by TEE compared to TIE for ASA (10 vs 4); left atrialllA)
and LA appendage thrombi (20 vs 3); lA myxoma (4 vs 2); vegetation (2 vs
1); patent foramen ovale (4 vs 0); spontaneous echo contrast effect (11 vs 1)
and aortic debris (10 vs 0). These observations suggest increased ability of
TEE in the detection of potential cardiac sources of emboli with significant
impact on the treatment strategy. Whether TEE should be the initial choice
of test in patients with suspected systemic emboli remains to the defined.
Implantable Cardioverter Defibrillators:
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1736-1 I Driving Safety in Patients with Implantable
Cardioverter-Defibrillators: A Single Center
Experience
Edward T Keelan, Anwer Dhala, Jasbir Sra, Kathi Axtell, Cheryl Maglio,
Mohammad R. Jazayeri, Zalmen Blanck, Sanjay Deshpande, Michael Biehl,
Masood Akhtar. Sinai Samaritan/Sf. Luke's Medical Center, Milwaukee, WI
There are as yet no clear guidelines regarding driving after cardioverter-
defibrillator (ICD) implantation. At this Institution, depending on their mode
of presentation patients (Pts) are advised to abstain from driving for 1-3
months after ICD implantation. Those without any syncopal episodes are
then allowed to drive if otherwise fit. To assess the safety of this approach,
we conducted a retrospective databank analysis of 635 Pts (508 males) of
mean age 62.5 ± 11.0 yrs who have been followed for a mean of 3.2 ± 2.4 yrs
(range 3 mth - 12yrs). Follow-up is complete on 629 Pts. The baseline char-
acteristics were: coronary artery disease in 80.5%, mean ejection fraction
33 ± 14% (n = 603) and 92.8% were in NYHA Class I or II. The presenting
arrhythmia was unstable VTNF in 55.5%, stablelnonsustained VT in 32.3%,
and was undocumented in 12.2%. We reviewed details on all Pts who had
had syncopal shocks (SS) or sudden cardiac death. There were 49 Pts who
had SS; lOaf these had 2:2 S5. The mean time to first SS was 18.8 ± 17.1
months after ICD implant. Only 1 Pt had a SS while driving (66 months after
first ICD implant); this did not result in a collision. There were 127 deaths
of which 22 were classified as sudden cardiac death. One Pt died suddenly
while driving 3 months post implant but did not cause injury to anyone else.
Conclusion; In this series, motor vehicle accidents resulting from syncopal
ICD shocks or sudden death occurred rarely. These results suggest that the
majority of Pts can be safely permitted to drive 1-3 months after ICD implant.
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1736-21 Should Patients be Permitted to Drive After
Cardioverter Defibfillator Implantation?
Hans-Joachim Trappe, Werner Schahl, Paul Wenzlaff. University Hospital Hannover,
Germany
It is unclear whether patients should be permitted to drive after cardioverter
defibrillator (ICD) implantation, or not. Therefore, questionnaires regarding
driVing have been completed by 162 patients (pts) who underwent ICD im-
plantation between 1/84 - 8/94. The mean follow-up of the pts population
